Company: INTS
Filing Date: 2025-06-13
Form Type: 8-K
Source: 0001628280-25-031311
Chunk: 0

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-06-13
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01

Entry into a Material Definitive Agreement

.

On June 11, 2025, Intensity Therapeutics, Inc. (the “ Company”) entered into an underwriting agreement (the “ Underwriting Agreement”) by and between ThinkEquity LLC (the “ Underwriter”) relating to the issuance and sale of an aggregate of 6,675,000 shares (the “ Firm Shares”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock”), to the Underwriter at a price to the public of $0.30 per share (the “ Offering”). Pursuant to the terms of the Underwriting Agreement, the Company granted to the Underwriter a 45-day option to purchase up to an additional 1,001,250 shares of Common Stock in the Offering (the “ Option Shares” and together with the Firm Shares, the “ Shares”). The Underwriter exercised its option in full to purchase the 1,001,250 Option Shares at the public offering price on June 12, 2025. The Offering, including the exercise of the Underwriter’s over-allotment option, closed on June 13, 2025. All of the Shares were sold by the Company. Pursuant to the Underwriting Agreement, the Company also agreed to issue to the Underwriter and/or its designees warrants to purchase up to 383,812 shares of Common Stock (the “ Representative’s Warrants”), which equals 5% of the Shares purchased in the Offering, such warrants to be exercisable as set forth in the Representative’s Warrant Agreement attached as Exhibit A to the Underwriting Agreement.

The net proceeds to the Company from the Offering, including the exercise of the Underwriter’s over-allotment option, are approximately $1.9 million after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for the enrollment of patients and to reach data read out in the INVINCIBLE-4 Study (expected in the first half of 2026), for the treatment of existing patients enrolled in the INVINCIBLE-3 Study (including the supply of drug product, maintenance of the study’s database, and the continued safety monitoring and pharmacovigilance in the study), and for working capital and general corporate purposes

The Shares are being offered and sold pursuant to a prospectus supplement, dated June 11, 2025 (the “ Prospect